In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2

Kausar Begam Riaz Ahmed, Steven L. Warner, Andrew Chen, Eric S. Gourley, Xiaohui Liu, Hariprasad Vankayalapati, Roberto Nussenzveig, Josef T. Prchal, David J. Bearss, Charles J. Parker

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: Constitutive activation of the Janus kinase 2 (JAK2) due to a somatic mutation (JAK2V617F) arising in hematopoietic stem cells plays a central role in the pathophysiology of myeloproliferative neoplasms (MPNs). To investigate the hypothesis that drugs that inhibit JAK2 have therapeutic potential, we developed a small molecule inhibitor, SGI-1252, that targets the adenosine triphosphate-binding and solvent pocket of the protein. Materials and Methods: Established cells lines each expressing different JAK2V617F copy numbers, a cell line transfected with wild-type and mutant JAK2, ex vivo expanded erythroid progenitor cells from patients with MPNs, and a murine xenograft model were used to characterize the activity of SGI-1252. Results: In vitro studies showed that SGI-1252 potently inhibits the kinase activity of wild-type JAK2, JAK2V617F and JAK1, but not JAK3. SGI-1252 blocked phosphorylation of signal transducers and activators of transcription 5, a downstream target of JAK2 and inhibited expression of the JAK2-dependent antiapoptotic gene BCL-XL. Additional studies confirmed induction of apoptosis in JAK2V617F-positive cell lines by SGI-1252. Moreover, cell lines transfected with either wild-type JAK2 or JAK2V617F were equally susceptible to the antiproliferative effects of SGI-1252 and the antiproliferative activity of SGI-1252 toward ex vivo-expanded erythroid progenitors from patients with polycythemia vera and primary myelofibrosis appeared independent of the JAK2V617F allele burden. Pharmacodynamic studies in a murine xenograft model demonstrated both anti-tumor activity and inhibition of signal transducers and activators of transcription 5 phosphorylation by SGI-1252, and the drug was active and well-tolerated whether delivered intraperitoneally or orally. Conclusions: Together, these studies support further development of SGI-1252 for clinical use.

Original languageEnglish (US)
Pages (from-to)14-25
Number of pages12
JournalExperimental Hematology
Volume39
Issue number1
DOIs
StatePublished - Jan 2011
Externally publishedYes

Fingerprint

Janus Kinase 2
STAT5 Transcription Factor
Cell Line
Heterografts
Phosphorylation
SGI-1252
In Vitro Techniques
Neoplasms
Polycythemia Vera
Erythroid Precursor Cells
Primary Myelofibrosis
Hematopoietic Stem Cells
Pharmaceutical Preparations
Phosphotransferases
Adenosine Triphosphate
Alleles
Apoptosis

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Genetics
  • Molecular Biology
  • Hematology

Cite this

Riaz Ahmed, K. B., Warner, S. L., Chen, A., Gourley, E. S., Liu, X., Vankayalapati, H., ... Parker, C. J. (2011). In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2. Experimental Hematology, 39(1), 14-25. https://doi.org/10.1016/j.exphem.2010.09.013

In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2. / Riaz Ahmed, Kausar Begam; Warner, Steven L.; Chen, Andrew; Gourley, Eric S.; Liu, Xiaohui; Vankayalapati, Hariprasad; Nussenzveig, Roberto; Prchal, Josef T.; Bearss, David J.; Parker, Charles J.

In: Experimental Hematology, Vol. 39, No. 1, 01.2011, p. 14-25.

Research output: Contribution to journalArticle

Riaz Ahmed, KB, Warner, SL, Chen, A, Gourley, ES, Liu, X, Vankayalapati, H, Nussenzveig, R, Prchal, JT, Bearss, DJ & Parker, CJ 2011, 'In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2', Experimental Hematology, vol. 39, no. 1, pp. 14-25. https://doi.org/10.1016/j.exphem.2010.09.013
Riaz Ahmed KB, Warner SL, Chen A, Gourley ES, Liu X, Vankayalapati H et al. In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2. Experimental Hematology. 2011 Jan;39(1):14-25. https://doi.org/10.1016/j.exphem.2010.09.013
Riaz Ahmed, Kausar Begam ; Warner, Steven L. ; Chen, Andrew ; Gourley, Eric S. ; Liu, Xiaohui ; Vankayalapati, Hariprasad ; Nussenzveig, Roberto ; Prchal, Josef T. ; Bearss, David J. ; Parker, Charles J. / In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2. In: Experimental Hematology. 2011 ; Vol. 39, No. 1. pp. 14-25.
@article{44262e855dd742879db757114cab7b53,
title = "In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2",
abstract = "Objective: Constitutive activation of the Janus kinase 2 (JAK2) due to a somatic mutation (JAK2V617F) arising in hematopoietic stem cells plays a central role in the pathophysiology of myeloproliferative neoplasms (MPNs). To investigate the hypothesis that drugs that inhibit JAK2 have therapeutic potential, we developed a small molecule inhibitor, SGI-1252, that targets the adenosine triphosphate-binding and solvent pocket of the protein. Materials and Methods: Established cells lines each expressing different JAK2V617F copy numbers, a cell line transfected with wild-type and mutant JAK2, ex vivo expanded erythroid progenitor cells from patients with MPNs, and a murine xenograft model were used to characterize the activity of SGI-1252. Results: In vitro studies showed that SGI-1252 potently inhibits the kinase activity of wild-type JAK2, JAK2V617F and JAK1, but not JAK3. SGI-1252 blocked phosphorylation of signal transducers and activators of transcription 5, a downstream target of JAK2 and inhibited expression of the JAK2-dependent antiapoptotic gene BCL-XL. Additional studies confirmed induction of apoptosis in JAK2V617F-positive cell lines by SGI-1252. Moreover, cell lines transfected with either wild-type JAK2 or JAK2V617F were equally susceptible to the antiproliferative effects of SGI-1252 and the antiproliferative activity of SGI-1252 toward ex vivo-expanded erythroid progenitors from patients with polycythemia vera and primary myelofibrosis appeared independent of the JAK2V617F allele burden. Pharmacodynamic studies in a murine xenograft model demonstrated both anti-tumor activity and inhibition of signal transducers and activators of transcription 5 phosphorylation by SGI-1252, and the drug was active and well-tolerated whether delivered intraperitoneally or orally. Conclusions: Together, these studies support further development of SGI-1252 for clinical use.",
author = "{Riaz Ahmed}, {Kausar Begam} and Warner, {Steven L.} and Andrew Chen and Gourley, {Eric S.} and Xiaohui Liu and Hariprasad Vankayalapati and Roberto Nussenzveig and Prchal, {Josef T.} and Bearss, {David J.} and Parker, {Charles J.}",
year = "2011",
month = "1",
doi = "10.1016/j.exphem.2010.09.013",
language = "English (US)",
volume = "39",
pages = "14--25",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2

AU - Riaz Ahmed, Kausar Begam

AU - Warner, Steven L.

AU - Chen, Andrew

AU - Gourley, Eric S.

AU - Liu, Xiaohui

AU - Vankayalapati, Hariprasad

AU - Nussenzveig, Roberto

AU - Prchal, Josef T.

AU - Bearss, David J.

AU - Parker, Charles J.

PY - 2011/1

Y1 - 2011/1

N2 - Objective: Constitutive activation of the Janus kinase 2 (JAK2) due to a somatic mutation (JAK2V617F) arising in hematopoietic stem cells plays a central role in the pathophysiology of myeloproliferative neoplasms (MPNs). To investigate the hypothesis that drugs that inhibit JAK2 have therapeutic potential, we developed a small molecule inhibitor, SGI-1252, that targets the adenosine triphosphate-binding and solvent pocket of the protein. Materials and Methods: Established cells lines each expressing different JAK2V617F copy numbers, a cell line transfected with wild-type and mutant JAK2, ex vivo expanded erythroid progenitor cells from patients with MPNs, and a murine xenograft model were used to characterize the activity of SGI-1252. Results: In vitro studies showed that SGI-1252 potently inhibits the kinase activity of wild-type JAK2, JAK2V617F and JAK1, but not JAK3. SGI-1252 blocked phosphorylation of signal transducers and activators of transcription 5, a downstream target of JAK2 and inhibited expression of the JAK2-dependent antiapoptotic gene BCL-XL. Additional studies confirmed induction of apoptosis in JAK2V617F-positive cell lines by SGI-1252. Moreover, cell lines transfected with either wild-type JAK2 or JAK2V617F were equally susceptible to the antiproliferative effects of SGI-1252 and the antiproliferative activity of SGI-1252 toward ex vivo-expanded erythroid progenitors from patients with polycythemia vera and primary myelofibrosis appeared independent of the JAK2V617F allele burden. Pharmacodynamic studies in a murine xenograft model demonstrated both anti-tumor activity and inhibition of signal transducers and activators of transcription 5 phosphorylation by SGI-1252, and the drug was active and well-tolerated whether delivered intraperitoneally or orally. Conclusions: Together, these studies support further development of SGI-1252 for clinical use.

AB - Objective: Constitutive activation of the Janus kinase 2 (JAK2) due to a somatic mutation (JAK2V617F) arising in hematopoietic stem cells plays a central role in the pathophysiology of myeloproliferative neoplasms (MPNs). To investigate the hypothesis that drugs that inhibit JAK2 have therapeutic potential, we developed a small molecule inhibitor, SGI-1252, that targets the adenosine triphosphate-binding and solvent pocket of the protein. Materials and Methods: Established cells lines each expressing different JAK2V617F copy numbers, a cell line transfected with wild-type and mutant JAK2, ex vivo expanded erythroid progenitor cells from patients with MPNs, and a murine xenograft model were used to characterize the activity of SGI-1252. Results: In vitro studies showed that SGI-1252 potently inhibits the kinase activity of wild-type JAK2, JAK2V617F and JAK1, but not JAK3. SGI-1252 blocked phosphorylation of signal transducers and activators of transcription 5, a downstream target of JAK2 and inhibited expression of the JAK2-dependent antiapoptotic gene BCL-XL. Additional studies confirmed induction of apoptosis in JAK2V617F-positive cell lines by SGI-1252. Moreover, cell lines transfected with either wild-type JAK2 or JAK2V617F were equally susceptible to the antiproliferative effects of SGI-1252 and the antiproliferative activity of SGI-1252 toward ex vivo-expanded erythroid progenitors from patients with polycythemia vera and primary myelofibrosis appeared independent of the JAK2V617F allele burden. Pharmacodynamic studies in a murine xenograft model demonstrated both anti-tumor activity and inhibition of signal transducers and activators of transcription 5 phosphorylation by SGI-1252, and the drug was active and well-tolerated whether delivered intraperitoneally or orally. Conclusions: Together, these studies support further development of SGI-1252 for clinical use.

UR - http://www.scopus.com/inward/record.url?scp=78650198723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650198723&partnerID=8YFLogxK

U2 - 10.1016/j.exphem.2010.09.013

DO - 10.1016/j.exphem.2010.09.013

M3 - Article

VL - 39

SP - 14

EP - 25

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 1

ER -